Suppliers and packagers for differin

differin

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Galderma Labs Lp	DIFFERIN	adapalene	CREAM;TOPICAL	020748	NDA	GALDERMA LABORATORIES, L.P	0299-5915-45	1 TUBE in 1 CARTON (0299-5915-45) / 45 g in 1 TUBE	2009-11-24
Galderma Labs Lp	DIFFERIN	adapalene	CREAM;TOPICAL	020748	NDA AUTHORIZED GENERIC	Padagis Israel Pharmaceuticals Ltd	45802-453-84	1 TUBE in 1 CARTON (45802-453-84) / 45 g in 1 TUBE	2010-10-26
Galderma Labs Lp	DIFFERIN	adapalene	GEL;TOPICAL	020380	NDA	Galderma Laboratories, L.P.	0299-4910-00	1 TUBE in 1 BLISTER PACK (0299-4910-00) / 2 g in 1 TUBE	2016-07-08

Suppliers for the Pharmaceutical Drug: Differin

Last updated: July 30, 2025

Introduction

Differin (adapalene) is a topical retinoid primarily prescribed for the treatment of acne vulgaris. Originally developed by Galderma, the drug’s market presence has expanded globally, with multiple suppliers and manufacturing entities involved in its production and distribution. Understanding the landscape of Differin suppliers is vital for stakeholders within the pharmaceutical supply chain, including distributors, healthcare providers, and policymakers, to ensure drug quality, supply security, and compliance with regulatory standards.

Manufacturers of Differin (Adapalene)

Galderma: The Original Supplier

Galderma Laboratories LLC pioneered Differin’s development and remains the primary patent holder and original manufacturer. As a leading global dermatology-focused pharmaceutical company, Galderma has proprietary rights over adapalene formulations, controlling major markets, especially in North America and Europe. The company’s facilities adhere to stringent Good Manufacturing Practice (GMP) standards, ensuring the integrity and efficacy of the medication.

Generic Manufacturers

Following the expiration of Differin’s patent protections in various regions, multiple generic pharmaceutical companies have entered the market, supplying biosimilar or generic versions of adapalene:

• Eli Lilly & Co.
  Although better known for other pharmaceuticals, Lilly has reportedly been involved in producing adapalene formulations, often through licensing agreements or licensing niche manufacturing rights.

• Ranbaxy (now part of Sun Pharma)
  As a prominent producer of generic dermatologicals, Ranbaxy has historically manufactured adapalene creams and gels, distributing them in multiple markets.

• Cipla
  A major Indian pharmaceutical manufacturer, Cipla produces generic adapalene formulations for local and international markets, adhering to international quality standards.

• Mylan (now part of Viatris)
  Known for its broad portfolio, Mylan manufactures adapalene generics, contributing to the drug’s global availability.

• Laboratoires Thea and other European manufacturers
  Certain local European firms have developed proprietary generic products, often marketed under different brand names but containing adapalene.

Contract Manufacturing Organizations (CMOs)

Beyond branded manufacturers, several CMOs provide active pharmaceutical ingredient (API) production or finished dosage forms for various brand owners and generic firms. These organizations facilitate scalability and supply chain flexibility but operate under strict regulatory oversight.

Supply Chain Considerations

The supply chain of Differin involves various stages:

• API Production: Mainly conducted in India, China, and some European facilities, where high-volume synthesis of adapalene occurs.
• Formulation and Packaging: Often managed by regional pharmaceutical companies, with manufacturing plants across North America, Europe, and Asia.
• Distribution: Involves licensed distribution partners, wholesalers, and pharmacies, requiring compliance with local regulations and quality standards.

Regulatory and Quality Assurance

Ensuring the safety of Differin involves adherence to the regulatory standards set by agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and counterparts worldwide. Suppliers must demonstrate compliance through rigorous inspections and pharmacovigilance programs.

Manufacturers and suppliers obtaining approvals for generic adapalene must submit bioequivalence and stability data confirming therapeutic equivalence to the innovator product. Quality assurance measures are critical, especially as substitutions are made across different suppliers.

Market Dynamics and Supplier Competition

The expiration of patent exclusivity in key markets has increased competition, leading to:

• Price reductions: Generics have driven down costs, enhancing accessibility.
• Supply diversification: Multiple suppliers reduce dependency on a single source, mitigating supply risks.
• Innovation and formulation variations: Suppliers experiment with combining adapalene with other active ingredients (e.g., benzoyl peroxide) to expand product portfolios.

The increasing demand for dermatological products, driven by rising acne prevalence globally, incentivizes suppliers to expand manufacturing capacities and secure long-term licensing agreements.

Challenges in the Differin Supply Chain

Supply chain risks include geopolitical disruptions, quality control lapses, regulatory delays, and raw material shortages. The reliance on Asian API producers underscores the need for diversified sourcing strategies and robust supplier qualification processes.

Furthermore, counterfeit products and substandard formulations pose risks, emphasizing the importance of procurement from verified suppliers with stringent regulatory compliance.

Future Outlook

The pipeline for new formulations and combination products suggests ongoing innovation in Differin supply. Advances in API synthesis techniques, sustainable manufacturing practices, and digital tracking (e.g., serialization) will improve supply chain resilience and product authenticity.

Additionally, potential patent battles and regulatory changes in emerging markets could shape supplier landscapes, creating both challenges and opportunities for existing and new players.

Key Takeaways

• Original Manufacturer Dominance: Galderma remains the primary producer of Differin, maintaining quality through rigorous manufacturing standards.
• Growing Generic Market: Multiple Asian and European companies have licensed or developed generic adapalene formulations post-patent expiry, increasing market competition.
• Supply Chain Diversification: Reliance on API suppliers from India and China necessitates diversified sourcing to mitigate risks.
• Regulatory Compliance: Suppliers must adhere to global standards and submit necessary data to gain or retain market authorization.
• Innovation and Expansion: New formulations and combination products signal ongoing growth opportunities, driven by supplier innovation.

---

FAQs

1. Who are the main suppliers of Differin (adapalene) globally?
Main suppliers include Galderma (original manufacturer), with numerous generics produced by companies such as Cipla, Mylan (Viatris), Ranbaxy (Sun Pharma), and regional European manufacturers. API production is primarily based in India and China.

2. What are the challenges faced by Differin suppliers?
Challenges include potential supply disruptions due to geopolitical issues, raw material shortages, stringent regulatory requirements, quality assurance, and counterfeit risks.

3. How has the market for Differin evolved post-patent expiry?
The market has become more competitive with a surge in generic manufacturers, leading to lower prices, increased accessibility, but also heightened supply chain complexity.

4. What role do Contract Manufacturing Organizations play in Differin’s supply chain?
CMOs produce APIs and finished dosage forms, enabling scalability and flexibility while maintaining regulatory compliance.

5. What future trends could impact Differin suppliers?
Innovation in combination products, sustainable manufacturing processes, digital supply chain tracking, and regulatory shifts in emerging markets are likely to influence supplier strategies.

---

Sources:

[1] Galderma official website. "Differin (adapalene) information."
[2] U.S. Food and Drug Administration (FDA). "Approved Drug Products with Therapeutic Equivalence Evaluations."
[3] European Medicines Agency (EMA). "Summary of Product Characteristics for adapalene."
[4] Market research reports on dermatology pharmaceuticals.
[5] Industry publications on generic drug manufacturing trends.